Privacy Analytics, Inc. announced the availability of a new solution designed to enable pharmaceutical companies to share clinical trials data while protecting the privacy of the individual patients.
Privacy Analytics, Inc. announced the availability of a new solution designed to enable pharmaceutical companies to share clinical trials data while protecting the privacy of the individual patients. Privacy Analytics' Open Clinical Trials Data Review, which runs on the company's automated risk-assessment, data request, PARAT software, compares existing industry anonymization approaches and finds privacy gaps.
The new offering accelerates the ability of pharmaceutical companies to meet increasing requests for individual-level participant data and clinical study reports by academicinstitutions, patients and other third-parties.
For privacy, regulatory and medical affairs executives, Privacy Analytics now provides:
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.